Double immune blockade aims to flush out hidden HIV
NCT ID NCT07692932
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study investigates whether combining two immune checkpoint inhibitors—one targeting GARP:TGF-β1 and another targeting PD-1—can better reactivate and eliminate dormant HIV-infected cells. Using blood samples from people with HIV-1 on suppressive antiretroviral therapy, researchers will measure if this 'shock-and-kill' approach reduces the viral reservoir and boosts immune responses. The goal is to find a strategy that could lead to an HIV cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GARP:TGF-β1 and PD-1 blockade (immune checkpoint inhibitors)
- What this could lead to
- If successful, this approach could significantly shrink the hidden HIV reservoir, bringing us closer to a functional cure for HIV-1.
- What could go wrong
- This is an early ex vivo study using blood samples, not a full human trial. The combination may not work as hoped or could cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, 1200, Belgium
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo
- Long-acting HIV shot studied in patients with severe kidney problems
- RNA vaccine aims to control HIV without daily pills
- Herbal formula may help HIV patients whose immune systems Don't fully recover